#United States #New York #AI Diagnostics #AEYE Health #Dr. Pamela F. Gallin

AEYE Health Welcomes Dr. Pamela F. Gallin as Chief Medical Officer

AEYE Health, recognized as a pioneering force in AI-powered retinal diagnostics, has announced the appointment of Dr. Pamela F. Gallin as its Chief Medical Officer. This exciting development is set to spur AEYE Health’s rapid expansion of its innovative AEYE-DS retinal screening system across the United States.

Dr. Gallin is a highly respected figure in the field of ophthalmology, boasting over 43 years of clinical and academic experience. Currently serving as a Clinical Professor of Ophthalmology at the Morgan Stanley Children's Hospital and the Edward S. Harkness Eye Institute, both at Columbia University Medical Center, Dr. Gallin has made remarkable contributions to pediatric ophthalmology.

Her roles included Director Emeritus of Pediatric Ophthalmology and Adult Strabismus at NewYork-Presbyterian where she also served as an examiner for the American Board of Ophthalmology Board Examination. Dr. Gallin is celebrated for her advocacy in medical education and clinical practices, alongside being the author of significant publications in her field, including a comprehensive textbook and two advocacy books aimed at empowering patients.

In a statement about her new position, Dr. Gallin expressed her excitement to join such an innovative organization as AEYE Health, stating that it is “dedicated to delivering groundbreaking, point-of-care diagnostic technology directly to where patients need it most.” With her onboard, the company is poised to leverage her wealth of knowledge and skills to enhance AEYE-DS, already the fastest-growing solution in the US for diabetic retinopathy screening.

About AEYE-DS

AEYE Health is transforming ophthalmic care through the use of AI technology to facilitate retinal disease screening right at the point of care. Its major product, AEYE-DS, holds the distinction of being the only FDA-cleared system specifically designed to conduct AI diabetic eye exams without requiring any physician interpretation, making it incredibly accessible to clinics and hospitals. This innovative solution necessitates just one image per eye, with no need for dilation, simplifying the process of eye examinations and enabling healthcare professionals to detect potential eye diseases efficiently.

The importance of early detection in preventing blindness, especially for diabetic patients, cannot be overstated. AEYE-DS’s capability to deliver real-time screening without extensive prerequisites points toward a monumental shift in eye care methodologies, effectively bridging gaps in care that currently exist.

Zack Dvey-Aharon, Co-Founder and CEO of AEYE Health, articulated his enthusiasm regarding Dr. Gallin's appointment, emphasizing her extensive clinical expertise and commitment to advancing patient outcomes. “Her vast experience and industry connections will be vital as we continue to roll out innovative technologies to every point of care in the U.S.,” he noted.

Dr. Gallin’s leadership at AEYE Health symbolizes a significant step forward not only for the organization but also for the entire field of ophthalmology. By harnessing the capabilities of AI-driven technologies, AEYE Health is not just positioning itself as a leader in eye care but is also paving the way for a future where retinal screening is accessible to all, particularly underserved communities.

As AEYE Health continues to grow, Dr. Gallin’s expertise will undoubtedly play a pivotal role in furthering their mission of preventing blindness and enhancing the quality of life for patients nationwide. The commitment to innovation blended with a heartfelt passion for patient care is what makes AEYE Health a beacon in the realm of digital health solutions and ophthalmic care.